| Literature DB >> 34943111 |
Giulia Squillacioti1, Fulvia Guglieri1, Nicoletta Colombi2, Federica Ghelli1, Paola Berchialla3, Paolo Gardois2, Roberto Bono1.
Abstract
Physical activity may benefit health by modulating oxidative stress and inflammation. However, the selection of suitable exercise-induced oxidative stress biomarkers is still challenging. This study aimed at systematically summarizing the available evidence on exercise-induced oxidative stress measured in urine and/or saliva. Two meta-analyses including the most frequently quantified biomarkers of oxidative stress, namely, urinary isoprostane and DNA oxidation products, were performed. Three electronic databases (PubMed, EMBASE and Cochrane CENTRAL) were interrogated. Among 4479 records, 43 original articles were included in the systematic review and 11 articles were included in meta-analysis I and II, respectively. We observed a pooled trend of increase of urinary isoprostanes in response to physical activity (+0.95, 95% CI: -0.18; 2.09). In comparison with aerobic exercise, anaerobic training determined a greater induction of isoprostanes (+5.21, 95% CI: 2.76; 7.66, p < 0.0001), which were markedly increased after vigorous physical activity (+6.01, 95% CI: 1.18; 10.84, p < 0.001) and slightly decreased in response to exercise interventions protracted over time (e.g., months) (-1.19, 95% CI: -2.25; -0.12, p < 0.001). We recommend the most integrative approach of oxidative stress multi-marker panels in response to physical activity instead of selecting one preferential biomarker to quantify physical activity-induced oxidative stress in humans.Entities:
Keywords: non-invasive biomarker; oxidative stress; physical activity; public health; saliva; urine
Year: 2021 PMID: 34943111 PMCID: PMC8698343 DOI: 10.3390/antiox10122008
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1Step-by-step study selection process. Modified from: [20].
Study and participants characteristics as originally reported by the studies included in the systematic review. Quality assessment is study-design based.
| Study | Country | Design | Sample Population | Physical Activity | Main Findings | Quality Assessment | Ref. |
|---|---|---|---|---|---|---|---|
| Allgayer | Germany | RCT | ♂ 17 moderately active, age (SD) = 58 (2) | aerobic | ↑ Urinary 8-OH-dG. After 2 weeks of individualised aerobic exercise (30–40 min/Day) | High | [ |
| Almar | Spain | Longitudinal | ♂ 8 | mixed | N.S. changes in urinary 8-OH-dG normalised to creatinine. | Medium | [ |
| Arazi | Iran | Controlled before-after | ♀ 23 | aerobic | ↑ Salivary peroxidase | High | [ |
| Babaei | Iran | RCT | ♂ 25 | aerobic | ↓ Salivary CAT, Vitamin C. After treadmill run | Medium | [ |
| Chielle | Brazil | Before after | ♂ 27 | mixed | ↑ Salivary TBARS | High | [ |
| Córdova | Spain | Longitudinal | ♂ 8 | aerobic | ↑ Urinary isoprostane. After a cycling race | Medium | [ |
| Damirchi | Iran | Controlled before-after | ♂ 10 | aerobic | ↑ Salivary peroxidase. | Medium | [ |
| Deminice | Brazil | Before after | ♂ 11 | anaerobic | ↑ Salivary UA. N.S. changes in TBARS, AOPP, GSH and lipid hydroperoxides | High | [ |
| Devries | Canada | Controlled before-after | ♀ 24 | aerobic | ↓ Urinary 8-OH-dG | High | [ |
| Gargallo | Spain | RCT | ♀ 36 | anaerobic | ↑ Urinary 8-OH-dG and ↓ Urinary 8-OH-dG, after high and moderate exercise intensity, respectively | Medium | [ |
| Hartmann | Austria Germany | Before after | ♂ 3 ♀ 3 | aerobic | ↑ Urinary 8-OH-dG. After a 24 h short-distance triathlon | High | [ |
| Hofer | Italy | RCT | ♂ 5 ♀12 | aerobic | Urinary nucleic acid oxidation products were not significantly different from baseline following 12-month intervention program | Medium | [ |
| Jackson | USA | RCT | ♂ 23 ♀ 6 | aerobic | ↑ Urinary isoprostane, N.S. changes in urinary H2O2 found after 50-W bicycle | High | [ |
| Karstoft | Denmark | Randomised crossover trial | ♂ 11 ♀ 3 | aerobic | N.S. changes in urinary isoprostane after 60 min of supervised waling on a treadmill | High | [ |
| Lessiani | Italy | Before after | ♂ 12 ♀ 6 | aerobic | ↓ Urinary isoprostane. After an eight-week aerobic | High | [ |
| Margaritelis | Cyprus Greece | Before after | ♂ 98 | anaerobic | ↑ Urinary isoprostane 48 h after an acute isokinetic eccentric exercise bout | High | [ |
| Margonis | Greece | Before after | ♂ 12 | anaerobic | ↑ Urinary isoprostane 96 h after a 12-week resistance training protocol | Medium | [ |
| Medina | Spain | Longitudinal | ♂ 10 Age (SD) = 19.0 (1.7) | aerobic | ↓ Urinary total isoprostanes and | Medium | [ |
| Mendoza-Núñez | Mexico | Before after | ♀ 24 | aerobic | ↑ Salivary SOD and TAS | High | [ |
| Mercken | Netherlands | Controlled before-after | ♂ 11 ♀ 11 | aerobic | ↑ Urinary MDA in COPD patients shortly after submaximal exercise and maximal exercise before pulmonary rehabilitation | High | [ |
| Mikami | Japan | Controlled before-after | ♂ 7 | aerobic | ↑ Urinary allantoin shortly after moderate intensity cycling exercise. N.S. changes of urate nor TBARS | High | [ |
| Nemoto | Japan | Before after | ♂ 18 | aerobic | ↑ Urinary 8-OH-dG in COPD (Stage IV) following 8-week pulmonary rehabilitation and aerobic training | High | [ |
| Nikolaidis | Cyprus Greece | Before after | ♂ 20 | aerobic | ↑ Urinary isoprostane shortly after a running protocol on a treadmill | High | [ |
| Nikolaidis | Cyprus Greece | Before after | ♂ 20 | anaerobic | ↑ Urinary isoprostane in elderly shortly after a single bout of isokinetic eccentric exercise | High | [ |
| Nojima | Japan | RCT | ♂ 59 ♀ 28 | aerobic | ↓ Urinary 8-OH-dG after 12-month program of aerobic exercise either self-paced either in a fitness centre | High | [ |
| Orhan | Netherlands | Case series self-controlled | ♂ 18 | aerobic | ↑ Urinary 8-OH-dG 1 day after 1 h cycling bout ( | Medium | [ |
| Parise | Canada | Before after | ♂ 15 ♀ 15 | anaerobic | ↓ Urinary 8-OH-dG. | High | [ |
| Poulsen | Denmark | Before after | ♂ 23 | aerobic | ↑ Urinary 8-OH-dG after a 30-day program of vigorous exercise (6 days per week, 8–11 h per day) | Medium | [ |
| Radák | Canada Hungary | Longitudinal | ♂ 5 | aerobic | ↑ Urinary 8-OH-dG after the first day (120 km) of a 4-day race (marathon) | Medium | [ |
| Rall | USA | Controlled before-after | ♂ 6 ♀ 10 | anaerobic | N.S. changes in urinary 8-OH-dG following a 12-week progressive resistance training | Medium | [ |
| Rietjens | Netherlands | Before after | ♂ 8 | anaerobic | ↑ Urinary isoprostane following a single session of resistance exercise | Medium | [ |
| Rodrigues de Araujo | Brazil | Before after | ♂ 32 | anaerobic | ↓ Salivary UA and N.S. changes in salivary TBARS, MDA, GSH, GSSG, SOD and CAT after acute high intensity exercise | High | [ |
| Rowlands | Canada | Longitudinal | ♂ 16 ♀ 3 | aerobic | ↑ Urinary isoprostane | Medium | [ |
| Samia | Egypt | Longitudinal | ♀ 8 | mixed | ↑ Urinary 8-OH-dG after the first day of the National First, Class Republic Competition consisting of 100 m run, high jump, shot put and 200 m run. | Medium | [ |
| Samjoo | Canada | Before after | ♂ 18 | aerobic | ↓ Urinary isoprostane and | High | [ |
| Santilli | Italy | Before after | ♂ 15 ♀ 7 | aerobic | ↓ Urinary isoprostane after 8-week aerobic training program | High | [ |
| Schmitz | USA | Before after | ♀ 15 | aerobic | ↓ Urinary isoprostane after 15 weeks of aerobic exercise | High | [ |
| Sumida | Japan | Controlled before-after | ♂ 28 | aerobic | N.S. changes in urinary 8-OH-dG after a single bout of intensive exercise | High | [ |
| Vempati | India | RCT | ♂ 13 ♀ 16 | aerobic | N.S. changes in urinary 11β-PGF2α after 8-week yoga intervention | Medium | [ |
| Vezzoli | Italy | Before after | ♂ 20 | aerobic | ↑ Urinary 8-OH-dG after either high-intensity discontinuous training and moderate-intensity continuous training | High | [ |
| Vezzoli | Italy | Longitudinal | ♂ 10 ♀ 14 | aerobic | ↑ Urinary isoprostane and 8-OH-dG after ultra-endurance exercise | Medium | [ |
| Viana-Gomes | Brazil | Before after | ♂ 8 | mixed | N.S. changes in salivary TAC, UA. | High | [ |
| Viguie | USA | Before after | ♂ 11 | aerobic | N.S. changes of urinary 8-OH-dG following single exercise bout on a cycle ergometer | Medium | [ |
♂: males; ♀: females; ↑: increase; ↓; decrease; NA: Not Available; RCT: Randomised Controlled Trial; VO2max: maximal oxygen consumption; Vo2peak: peak oxygen uptake; RM: Repetition Maximum; W: Watts, cycling power.
Biomarkers of oxidative stress measured in urine and/or saliva at baseline and after physical activity intervention. Data are presented as originally reported by the studies as follows: * mean (SEM), † median (IQR), § mean (SD).
| Study | Sample | Urinary Biomarker | Analytical Method | Urinary Baseline Measure | After Physical Activity | Salivary Biomarker | Analytical Method | Salivary Baseline Measure | After Physical Activity | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|
| Allgayer | 12 h | 8-oxo-dG | HPLC | moderate intensity 8.5 (2.0) § | 5.8 (1.5) § | -- | -- | -- | -- | [ |
| Almar | 12 h | 8-OH-dG | HPLC | 117.4 (38.1) * | 136.5 (54.8) * | -- | -- | -- | -- | [ |
| Arazi | spot | -- | -- | -- | -- | UA | Spectrophotometric | non-smokers 5.9 (0.8) * | 6.3 (0.8) * | [ |
| Arazi | spot | -- | -- | -- | -- | Peroxidase | Colorimetric | non-smokers 0.17 (0.07) * | 0.24 (0.08) * | |
| Babaei | spot | -- | -- | -- | -- | CAT | Spectrophotometric | 0.005 (0.001) § | 0.003 (0.001) § | [ |
| Babaei | spot | -- | -- | -- | -- | Vitamin C | Colorimetric | 0.274 (0.29) § | 0.221 (0.45) § | |
| Chielle | spot | TBARS | ELISA | 13.6 (7.3) § | 80.1 (14.3) § | TBARS | ELISA | 19.4 (11.7) § | 26.6 (18) § | [ |
| Córdova | spot | isoprostane | ELISA | 359 (71) § | 686 (139) § | -- | -- | -- | -- | [ |
| Damirchi | spot | -- | -- | -- | -- | Peroxidase | Spectrophotometric | 50% VO2max 3.22 (0.24) § | 3.59 (0.25) § | [ |
| Deminice | spot | -- | -- | -- | -- | TBARS | Colorimetric (Ellman’s reaction) | 2.0 (1.2) § | 2.5 (1.2) § | [ |
| Deminice | spot | -- | -- | -- | -- | Lipid hydroperoxide | Colorimetric | 10.2 (2.6) § | 11.4 (4.5)v | |
| Deminice | spot | -- | -- | -- | -- | AOPP | Spectrophotometric | 30.8 (14.8) § | 37.4 (17.7) § | |
| Deminice | spot | -- | -- | -- | -- | UA | Enzymatic | 2.1 (1.1) § | 3.1 (1.1) § | |
| Deminice | spot | -- | -- | -- | -- | GSH | Colorimetric (Ellman’s reaction) | 0.16 (0.08) § | 0.17 (0.08) § | |
| Devries | 24 h | isoprostane | ELISA | lean 54.41 (17.12) * | 37.97 (8.3) * | -- | -- | -- | -- | [ |
| Devries | 8-OH-2-dG | ELISA | lean 5.71 (1.31) * | 3.15 (0.76) * | -- | -- | -- | -- | ||
| Gargallo | spot | 8-OH-dG | HPLC | high intensity 2.12 (1.34) § | 3.64 (1.37) § | -- | -- | -- | -- | [ |
| Gargallo | GSH | Colorimetric | high intensity 22.71 (3.83) § | 20.23 (3.35) § | -- | -- | -- | -- | ||
| Gargallo | GSSG | Colorimetric | high intensity 0.23 (0.08) § | 0.25 (0.13) § | -- | -- | -- | -- | ||
| Gargallo | GSSG/GSH | Colorimetric | high intensity 1.05 (0.48) § | 1.29 (0.79) § | -- | -- | -- | -- | ||
| Hartmann | 24 h | 8-OH-dG | HPLC | 2.42 (1.26) § | 1.30 (0.23) § | -- | -- | -- | -- | [ |
| Hofer | 12 h | FapyGua | MS-MS | 4.50 (2.4) * | 3.25 (1.0) * | -- | -- | -- | -- | [ |
| Hofer | 8-oxoGua | MS-MS | 127 (28) * | 144 (44) * | -- | -- | -- | -- | ||
| Hofer | 8-oxoGuo | MS-MS | 6.28 (2.1) * | 5.34 (1.5) * | -- | -- | -- | -- | ||
| Hofer | 8-oxodGuo | MS-MS | 2.30 (0.74) * | 2.78 (0.82) * | -- | -- | -- | -- | ||
| Jackson | spot | isoprostane | HPLC-MSMS | 275 (184) † | 335 (295) † | -- | -- | -- | -- | [ |
| Jackson | H2O2 | Colorimetric | 30.8 (15.4) † | 38.5 (53.8) † | -- | -- | -- | -- | ||
| Karstoft | 24 h | isoprostane | ELISA | 1148 (127) * | 1051 (114) * | -- | -- | -- | -- | [ |
| Lessiani | 12 h | isoprostane | RIA | 320 (287–435) † | 209 (154–258) † | -- | -- | -- | -- | [ |
| Margaritelis | spot | isoprostane | ELISA | 690 (220) § | 950 (320) § | -- | -- | -- | -- | [ |
| Margonis | spot | isoprostane | ELISA | 1.65 (1.43;1.89) * | 3.90 (3.60;4.35) * | -- | -- | -- | -- | [ |
| Medina | 24 h | Total isoprostanes | UPLC | males 12,920 (4790) § | 9380 (2910) § | -- | -- | -- | -- | [ |
| Medina | isoprostane | UPLC | males 1714.3 (723.7) § | 1009.5 (485.5) § | -- | -- | -- | -- | ||
| Medina | 8-iso-15(R)-PGF2α | UPLC | males 634.2 (451.2) § | 1939 (841) § | -- | -- | -- | -- | ||
| Medina | 2,3-dinor-8-iso PGF2α | UPLC | males 4000 (875) § | 2887 (587.4) § | -- | -- | -- | -- | ||
| Medina | 2,3-dinor-11β-PGF2α | UPLC | males 3124.9 (1205) § | 2295 (682) § | -- | -- | -- | -- | ||
| Mendoza-Núñez | spot | -- | -- | -- | -- | SOD | Colorimetric | 1.62 (0.83) * | 2.79 (1.6) * | [ |
| Mendoza-Núñez | spot | -- | -- | -- | -- | TAS | Colorimetric | 0.53 (0.33) * | 0.70 (0.35) * | |
| Mendoza-Núñez | spot | -- | -- | -- | -- | TNF-alpha | Flow cytometry | 0.5119 (0.009) * | 4.2410 (0.435) * | |
| Mendoza-Núñez | spot | -- | -- | -- | -- | IL-1 beta | Flow cytometry | 783.62 (174.9) * | 624.97 (196.7) * | |
| Mendoza-Núñez | spot | -- | -- | -- | -- | IL-6 | Flow cytometry | 18.66 (7.25) * | 4.76 (1.93) * | |
| Mendoza-Núñez | spot | -- | -- | -- | -- | IL-8 | Flow cytometry | 4971.2 (835.0) * | 2242.4 (330.0) * | |
| Mendoza-Núñez | spot | -- | -- | -- | -- | IL-10 | Flow cytometry | 0.21 (2.5) * | 2.9 (1.5) * | |
| Mendoza-Núñez | spot | -- | -- | -- | -- | Lipid hydroperoxidase | 0.11 (0.07) § | 0.14 (0.09) § | ||
| Mercken | spot | MDA | HPLC | healthy subjects 0.28 (0.04) * | 0.29 (0.03) * | -- | -- | -- | -- | [ |
| Mikami | spot | Allantoin | HPLC | 40% VOmax 0.08 (0.002) * | 0.09 (0.001) * | -- | -- | -- | -- | [ |
| Mikami | TBARS | HPLC | 40% VO2max 2.80 (0.8) * | 2.76 (0.6) * | -- | -- | -- | -- | ||
| Mikami | Urate | UA B-test Wako | 40% VO2max 0.40 (0.06) * | 0.40 (0.06) * | -- | -- | -- | -- | ||
| Nemoto | spot | 8-OH-dG | ELISA | II–III COPD severity 16.6 (2.2) * | 17.8 (2.3) * | -- | -- | -- | -- | [ |
| Nikolaidis | spot | isoprostane | ELISA | muscle damaging 588.8 (315.4) * | 1126.17 (324.78) * | -- | -- | -- | -- | [ |
| Nikolaidis | spot | isoprostane | ELISA | young 430.4 (30.4) * | 434.8 (39) * | -- | -- | -- | -- | [ |
| Nojima | spot | 8-OH-dG | ELISA | Exercise in a fitness centre 10.3 (1.1) * | 9.3 (1.0) * | -- | -- | -- | -- | [ |
| Orhan | 24 h | 8-OH-dG | ELISA | 12.14 (5) * | 47.4 (15) * | -- | -- | -- | -- | [ |
| Orhan | MDA | HPLC | 1.45 (0.33) * | 1.74 (0.35) * | ||||||
| Parise | spot | 8-OH-dG | ELISA | 10783 (5856) § | 8897 (4030) § | -- | -- | -- | -- | [ |
| Poulsen | spot | 8-OH-dG | HPLC | 1.03 (0.59) § | 1.25 (0.59) § | -- | -- | -- | -- | [ |
| Radák | spot | 8-OH-dG | ELISA | 14.74 (2.50) § | 19.15 (2.50) § | -- | -- | -- | -- | [ |
| Rall | 24 h | 8-OH-dG | ELISA | healty elderly 24.82 (16.35) § | 15.50 (10.74) § | -- | -- | -- | -- | [ |
| Rietjens | spot | isoprostane | ELISA | 0.117 (0.021) * | 0.164 (0.030) * | -- | -- | -- | -- | [ |
| Rodrigues de Araujo | spot | -- | -- | -- | -- | TBARS | Colorimetric | 9.20 (3.13) § | 8.50 (2.43) § | [ |
| Rodrigues de Araujo | spot | -- | -- | -- | -- | MDA | Colorimetric | 5.40 (2.15) § | 5.37 (1.52) § | |
| Rodrigues de Araujo | spot | -- | -- | -- | -- | GSH | Colorimetric | 54.78 (3.57) § | 54.55 (9.57) § | |
| Rodrigues de Araujo | spot | -- | -- | -- | -- | GSSG | Colorimetric | 2.04 (1.18) § | 2.10 (1.13) § | |
| Rodrigues de Araujo | spot | -- | -- | -- | -- | UA | Colorimetric | 2.66 (1.33) § | 1.66 (0.92) § | |
| Rodrigues de Araujo | spot | -- | -- | -- | -- | SOD | Spectrophotometric | 32.6 (43.9) § | 37.4 (42.1) § | |
| Rodrigues de Araujo | spot | -- | -- | -- | -- | CAT | Colorimetric | 1.65 (1.53) § | 1.66 (2.90) § | |
| Rowlands | spot | isoprostane | ELISA | 84.9 (28.6) § | 112.6 (52.7) § | -- | -- | -- | -- | [ |
| Rowlands | 8-OH-dG | ELISA | 11166 (5613) § | 9045 (4813) § | -- | -- | -- | -- | ||
| Samia | spot | 8-OH-dG | ELISA | 23.78 (1.95) § | 25.96 (1.33) § | -- | -- | -- | -- | [ |
| Samjoo | 24 h | 8-OH-dG | ELISA | healthy 10399 (1600) * | 10319 (2480) * | -- | -- | -- | -- | [ |
| Samjoo | isoprostane | ELISA | healthy 1087 (104) * | 935 (88) * | -- | -- | -- | -- | ||
| Santilli | 24 h | isoprostane | RIA | 325 (287–508) * | 218 159–335) * | -- | -- | -- | -- | [ |
| Schmitz | 24 h | isoprostane | GC-MS | 78.79 (52.13) § | 52.19 (19.17) § | -- | -- | -- | -- | [ |
| Sumida | 24 h | 8-OH-dG | HPLC | treadmill exhaustion 1.67 (0.18) * | 1.61 (0.17) * | -- | -- | -- | -- | [ |
| Vempati | spot | isoprostane | ELISA | 455.4 (991) † | 26.9 (210) † | -- | -- | -- | -- | [ |
| Vezzoli | spot | 8-OH-dG | ELISA | moderate intensity 5.50 (0.66) § | 4.16 (0.40) § | -- | -- | -- | -- | [ |
| Vezzoli | spot | isoprostane | ELISA | 50 km running 0.42 (0.13) § | 0.60 (0.14) § | -- | -- | -- | -- | [ |
| Vezzoli | 8-OH-dG | ELISA | 50 km running 4.38 (1.16) § | 7.48 (1.16) § | -- | -- | -- | -- | ||
| Viana-Gomes | spot | -- | -- | -- | -- | TBARS | Colorimetric | 2.1 (0.3) * | 3.1 (0.4) * | [ |
| Viana-Gomes | -- | -- | -- | -- | TAC | Colorimetric | 41.8 (2.3) * | 44.2 (2.8) * | ||
| Viana-Gomes | -- | -- | -- | -- | UA | Colorimetric | 2.5 (0.3) * | 3.1 (0.4) * | ||
| Viguie | 24 h | 8-OH-dG | HPLC | 405.3 (44.8) * | 306.9 (54) * | -- | -- | -- | -- | [ |
Figure 2Salivary biomarkers of oxidative stress according to the studies included in the systematic review. Note: Data are reported as percentage changes after physical activity interventions and according to the significance level (i.e., NS = not significant). HI = high intensity of physical activity; MI = moderate intensity of physical activity; LI = low intensity of physical activity.
Figure 3Pooled effect of physical activity interventions and oxidative stress measured by urinary 8-OH-dG or 8-oxo-dG. Note: Data presented as sub-groups “A” and “B” refer to moderate-intensity physical activity and high-intensity physical activity, respectively. Data presented as sub-groups “A”, “B” and “C” refer to running on a treadmill until exhaustion, cycling until exhaustion and running for 20 km, respectively.
Figure 4Pooled effect of physical activity interventions and oxidative stress measured by urinary isoprostanes. Note: Data presented as sub-groups “A” and “B” refer to males and females, respectively.